for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

101.59USD

Change

1.66(+1.66%)

Volume

234,049

Today's Range

99.90

 - 

101.70

52 Week Range

61.62

 - 

102.89

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
99.93
Open
99.97
Volume
234,049
3M AVG Volume
127.34
Today's High
101.70
Today's Low
99.90
52 Week High
102.89
52 Week Low
61.62
Shares Out (MIL)
1,770.53
Market Cap (MIL)
178,257.00
Forward P/E
31.03
Dividend (Yield %)
1.43

Next Event

Q3 2020 Abbott Laboratories Earnings Release

Latest Developments

More

Abbott Receives FDA Approval For Ios-Compatible App Allowing People Living With Chronic Pain And Movement Disorders To Personalize Therapy Via Their Mobile Device

Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call

Abbott Reports Second-Quarter Earnings Per Share $0.30 From Continuing Operations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry

Medical Equipment & Supplies

Contact Info

100 Abbott Park Rd

ABBOTT PARK, IL

60064-3500

United States

+1.224.6676100

https://www.abbott.com

Executive Leadership

Miles D. White

Executive Chairman of the Board

Robert B. Ford

President, Chief Executive Officer, Chief Operating Officer, Director

Robert E. Funck

Chief Financial Officer, Executive Vice President - Finance

Hubert L. Allen

Executive Vice President, General Counsel, Secretary

Mary K. Moreland

Executive Vice President of Human Resources

Key Stats

1.95 mean rating - 21 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

27.4K

2018

30.6K

2019

31.9K

2020(E)

32.8K
EPS (USD)

2017

2.500

2018

2.880

2019

3.240

2020(E)

3.244
Price To Earnings (TTM)
58.24
Price To Sales (TTM)
5.67
Price To Book (MRQ)
5.83
Price To Cash Flow (TTM)
28.54
Total Debt To Equity (MRQ)
64.36
LT Debt To Equity (MRQ)
59.47
Return on Investment (TTM)
5.28
Return on Equity (TTM)
4.49

Latest News

Latest News

Abbott sees no hit to demand for COVID-19 tests from vaccine

Abbott Laboratories said on Thursday demand for its coronavirus tests will likely remain high even after a safe and effective vaccine is available as the medical device maker forecast full-year profit above analysts' estimates.

BRIEF-Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call

* ABBOTT CEO SAYS AT THE END OF JUNE, PROCEDURE VOLUMES REBOUNDED TO 90% OF PRE-CRISIS LEVELS ON AVERAGE IN U.S. - CONF CALL

REFILE-Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.

Abbott quarterly profit plunges as COVID-19 batters medical device unit

Abbott Laboratories on Thursday reported a 46.6% fall in second-quarter profit as the COVID-19 pandemic continued to batter its medical device unit.

BRIEF-Abbott Receives FDA Approval For Heart Rhythm Devices With Bluetooth Connectivity, Continuous Remote Monitoring

* ABBOTT RECEIVES FDA APPROVAL FOR NEW HEART RHYTHM DEVICES FEATURING BLUETOOTH CONNECTIVITY AND CONTINUOUS REMOTE MONITORING Source text for Eikon: Further company coverage:

BRIEF-Abbott, Tandem Diabetes Care Advance Development of Technologies for Insulin Delivery Systems

* ABBOTT - COS PARTNER TO INTEGRATE ABBOTT'S FREESTYLE LIBRE CONTINUOUS GLUCOSE MONITORING TECHNOLOGY WITH TANDEM'S INSULIN DELIVERY PRODUCTS Source text for Eikon: Further company coverage:

BRIEF-Abbott Laboratories Files For Potential 2-Part, Notes Offering

* ABBOTT LABORATORIES FILES FOR POTENTIAL 2-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/3hT6Zrw) Further company coverage:

BRIEF-Abbott Laboratories Files For Potential Debt Shelf Offering

* ABBOTT LABORATORIES SAYS IT FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source: (https://bit.ly/3i0wEim) Further company coverage:

U.S. FDA clears new version of Abbott's low-cost glucose monitor

The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device, helping the company build upon the success of its fastest-growing diabetes product.

BRIEF-Abbott's Freestyle Libre 2 Cleared In U.S. For Adults And Children With Diabetes

* ABBOTT'S FREESTYLE® LIBRE 2 ICGM CLEARED IN U.S. FOR ADULTS AND CHILDREN WITH DIABETES, ACHIEVING HIGHEST LEVEL OF ACCURACY AND PERFORMANCE STANDARDS

U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor

The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' continuous glucose monitoring device.

BRIEF-Abbott Declares Quarterly Dividend

* SETS QUARTERLY DIVIDEND OF $0.36PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Abbott's Interim Clinical Study Data on ID NOW COVID-19 Rapid Test Shows Strong Agreement to Lab-Based Molecular PCR Tests

* ABBOTT RELEASES INTERIM CLINICAL STUDY DATA ON ID NOW COVID-19 RAPID TEST SHOWING STRONG AGREEMENT TO LAB-BASED MOLECULAR PCR TESTS

Abbott says new data on rapid coronavirus test used in White House shows high accuracy

Abbott Laboratories on Thursday said an analysis of data from an ongoing study of its ID NOW rapid test, which is used in the White House and elsewhere to spot COVID-19, shows it is highly accurate when compared with industry-standard tests.

BRIEF-Abbott Announces Contract To Supply Millions Of IgG Lab-Based Antibody Tests To UK

* ABBOTT ANNOUNCES CONTRACT TO SUPPLY MILLIONS OF IGG LAB-BASED ANTIBODY TESTS TO UK GOVERNMENT

BRIEF-Abbott Announces Health Canada Authorization Under Covid-19 Interim Order And Immediate Availability Of Its Covid-19 Antibody Test In Canada

* ABBOTT ANNOUNCES HEALTH CANADA AUTHORIZATION UNDER COVID-19 INTERIM ORDER AND IMMEDIATE AVAILABILITY OF ITS COVID-19 ANTIBODY TEST IN CANADA

U.S. health secretary expresses confidence in Abbott's fast COVID-19 test

A top Trump administration official said on Friday the government still has confidence in Abbott Laboratories’ <ABT.N> speedy coronavirus test used at the White House, which regulators have warned could deliver inaccurate results.

U.S. regulator is reviewing Abbott's fast COVID test after studies raise accuracy concerns

The U.S. Food and Drug Administration said on Thursday that Abbott Laboratories’ speedy coronavirus test, which can deliver results within minutes and is used at the White House, could potentially be inaccurate but can still be used to test patients.

Britain approves Abbott's COVID-19 antibody test

Britain has given the green light to Abbott Laboratories <ABT.N> to produce a COVID-19 antibody test, shortly after it gave the same approval to Swiss drugmaker Roche Holding <ROG.S>, health officials said on Friday.

BRIEF-FDA Says Abbott's ID Now Point-Of-Care Test To Diagnose COVID-19 May Return False Negative Results

* CORONAVIRUS (COVID-19) UPDATE: FDA INFORMS PUBLIC ABOUT POSSIBLE ACCURACY CONCERNS WITH ABBOTT ID NOW POINT-OF-CARE TEST

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up